RxDoctor Payments Data

Erin Lassanske, NP

Family · Milwaukee, WINPI 1235135559

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,000 of the $14,363 with a category attached, or 62.7%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 94.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $5,146 and has fallen 93.5% since, to $335 in 2025. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,363in general payments, 2019–2025

Across 51 payments — averaging $281.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14K
  • Heartflow, Inc.$285
  • Medtronic$251
  • Boston Scientific$100
  • Novo Nordisk$52
  • Johnson & Johnson$29
  • plus $36 from 2 others

What the payments were for

  • Speaking & faculty fees$9,00063%
  • Travel & lodging$3,53125%
  • Food & beverage$1,83213%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,363 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$6,371
Medicare patients
53
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$245,446
XareltoRivaroxaban135$160,263
SotalolSotalol Hcl90$3,157
Flecainide Acetate42$3,004
Metoprolol Succinate195$2,592
Diltiazem 24hr Er (Cd)Diltiazem Hcl63$2,030
Amiodarone Hcl133$1,863
Metoprolol Tartrate84$679
Carvedilol46$455
Digoxin16$400
Atenolol23$259
Fludrocortisone Acetate11$239
Lisinopril38$218
Amlodipine Besylate31$188
Losartan Potassium32$170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$29$160,263135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.

Other family in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →